Haw Par's (SGX:H02) profit declined 5.5% in the second half of 2024 to SG$106.3 million from SG$112.4 million a year earlier, according to a filing with the Singapore Exchange on Friday.
Earnings per share decreased to SG$0.48 compared with SG$0.508 in the comparable period.
Revenue was up 4.8% year over year to SG$126.7 million from SG$120.9 million year over year, driven by higher sales from the healthcare division.
Shares of the pharmaceutical company were up over 7% in recent trading.